<DOC>
	<DOCNO>NCT00031499</DOCNO>
	<brief_summary>The purpose study determine azithromycin , drug approve treatment infection , effective syphilis ( sexually transmit disease ) standard treatment . Approximately 600 healthy adult , HIV-negative , age 18 55 year age , primary , secondary early latent syphilis , participate research study . Volunteers enrol 5 U.S. city Madagascar . Participants choose randomly ( chance ) receive 1 2 study drug : benzathine penicillin give ( 2 shot buttock ) 4 tablet azithromycin . Subjects report history penicillin allergy give either 2.0 g oral azithromycin 100 mg doxycycline take orally , twice day 14 day . Over 2 year , 10 visit require . Procedures include blood sample , physical exam , swabs sore .</brief_summary>
	<brief_title>Azithromycin/Bicillin Syphilis</brief_title>
	<detailed_description>Syphilis disease worldwide distribution . It cause genital ulceration , thereby amplify risk HIV acquisition transmission may cause congenital infection , spontaneous abortion , stillbirth untreated pregnant woman . About one third case , untreated , result late sequela include neurosyphilis , gumma formation cardiovascular involvement . This study multi-center , randomize , open-label trial evaluate efficacy azithromycin treat primary , secondary early latent syphilis HIV ( Human Immunodeficiency Virus ) uninfected volunteer . Up version 6.0 protocol volunteer follow 12 month . The protocol amend start version 7.0 include follow-up visit month 18 24 order capture possible `` late failure . '' Each subject randomize treatment group . If subject self-reported history penicillin allergy , subject randomize receive either single 2.0 gram dose azithromycin administer orally , 2.4 million unit benzathine penicillin G administer intramuscularly . Eligible patient report history penicillin allergy randomize ( use separate randomization schedule ) receive either single dose azithromycin doxycycline , 100 milligram , take orally , twice day 14 day . Block randomization use within clinical center subject allocate equal number either standard therapy azithromycin . Participants find ineligible study participation randomize treat , treat benzathine penicillin G ( doxycycline allergic penicillin ) continue follow-up safety evaluation . The treatment assignment blind . No attempt make recruit sufficient sample size among penicillin allergic subject attain desired power primary outcome . Therefore result see preliminary possible future trial confirmatory primary comparison . Although study endpoint determine 6 month , participant , follow-up visit 2 full year . At end 6 month evaluation period , participant classify one follow group : cure ; clinical response/serological nonresponse ; failure .</detailed_description>
	<mesh_term>Syphilis</mesh_term>
	<mesh_term>Penicillins</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Penicillin G Benzathine</mesh_term>
	<mesh_term>Penicillin G</mesh_term>
	<mesh_term>Penicillin G Procaine</mesh_term>
	<criteria>The subject 18 55 year age . The subject sign write informed consent . The subject untreated primary [ darkfield Treponema ( T. ) pallidum rapid , direct , fluorescent antibody darkfield ( DFATP ) ] positive genital ulcer , secondary ( base classical palmar/plantar rash , condylomata lata , mucous patch , etc . darkfield DFATP positive lesion ) , early latent syphilis ( e.g. , current reactive serologic test syphilis ( STS ) , document nonreactive STS document sexual exposure know early latent , primary secondary syphilis patient last 12 month ; identification sexual contact must occur within 60 day admission study ) . The subject laboratory evidence syphilis , i.e. , reactive serologic test syphilis ( RPR ) . The subject pregnant , document negative urine serum pregnancy test , lactate . The subject willing HIV test , , participate HIV counsel return clinic followup treatment . The subject reactive serologic test syphilis . The subject latent syphilis unknown duration , late latent syphilis evidence neurosyphilis . The subject know suspect allergy macrolide azalide antibiotic . The subject know suspect sexually transmitted disease ( STD ) , syphilis require treatment drug , azithromycin , active T. pallidum . The subject use antibiotic active T. pallidum precede 30 day . ( Note : use antimicrobial know NOT effective T. pallidum quinolones , sulfonamide , trimethoprim , metronidazole spectinomycin allow ) . The subject know HIV positive prior enrollment . The subject suspect known ongoing drug use might interfere study participation followup treatment . The subject history cardiovascular disease , know immunosuppression , know AIDS , might compromise response therapy . The subject judge investigator unlikely reliably participate study followup . The subject use investigational drug past 30 day . The subject condition may impair drug absorption ( malabsorption syndrome active peptic ulcer disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Azithromycin , Syphilis , Penicillin</keyword>
</DOC>